Clinical Evaluation of Evolocumab for the Treatment of Homozygous Familial Hypercholesterolemia in Chinese Patients

Therapeutics and Clinical Risk Management
doi 10.2147/tcrm.s193971
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Treatment of Homozygous Familial Hypercholesterolemia: Challenges and Latest Development

2016English

Pcv56 - Clinical and Economic Burden of Cardiovascular Disease and Value of Evolocumab Treatment in Patients With Heterozygous Familial Hypercholesterolemia in Sweden

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Homozygous Familial Hypercholesterolemia “Rare Disease”

Journal of Glycomics & Lipidomics
2014English

Recent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia

Current Atherosclerosis Reports
Cardiovascular MedicineCardiology
2016English

Surgical Treatment of Valvular and Supravalvular Aortic Stenosis in Homozygous Familial Hypercholesterolemia

General Thoracic and Cardiovascular Surgery
CardiologyCardiovascular MedicineMedicineSurgeryRespiratory MedicinePulmonary
2014English

Familial Hypercholesterolemia Phenotype in Chinese Patients Undergoing Coronary AngiographyHighlights

Arteriosclerosis, Thrombosis, and Vascular Biology
Cardiovascular MedicineCardiology
2017English

Phenotype Diversity Among Patients With Homozygous Familial Hypercholesterolemia: A Cohort Study

Atherosclerosis
Cardiovascular MedicineCardiology
2016English

Homozygous Familial Hypercholesterolemia Among French Canadians in Quebec Province

Arteriosclerosis: An Official Journal of the American Heart Association, Inc.
1989English

Efficacy of Evolocumab in Monogenic Versus Polygenic Hypercholesterolemia

CJC Open
Cardiovascular MedicineCardiology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy